Dr. Reddy's Laboratories Ltd.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Dr. Reddy's Laboratories Ltd.
Plus deals involving Debiopharm/SunRock, RefleXion/3B Pharmaceuticals, Pharmanovia/Sanofi and more.
With Biogen having put its biosimilars interests on the market, multiple bidders appear to be interested in the business. Dr Reddy’s has become the latest firm to be named in media reports as vying for a deal.
Two days after FDA advisory panel’s meeting to discuss whether oral phenylephrine is effective for nasal congestion, complaints filed in federal court in multiple states alleging manufacturers knowingly misled public about ingredient’s efficacy. FDA’s potential response to NDAC’S finding wouldn’t come as soon.
The founder and MD of investment bank Candle Partners reflects on key pharma M&A trends over the years and the shape of things to come including private equity action and how family-owned firms are weighing monetization and diversification options.
- Generic Drugs
- OTC, Consumer
- Other Names / Subsidiaries
- Aurigene Discovery Technologies
- OctoPlus N.V.
- Promius Pharma LLC
- Dr. Reddy's Research and Development B.V.
- Imperial Credit Private Limited
- Wockhardt Limited
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.